Non-small Cell Lung Cancer (NSCLC) Clinical Trials in Cleveland, Ohio

4 studies are recruiting for non-small cell lung cancer (nsclc) in Cleveland, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with resp…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University Hospitals Cleveland Medical Center ( Site 0119), Cleveland, Ohio
    Locations
    220 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06170788 on ClinicalTrials.gov

  2. A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

    A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University Hospitals Cleveland Medical Center, Cleveland, Ohio
    Locations
    259 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07361497 on ClinicalTrials.gov

  3. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Exelixis Clinical Site #10, Cleveland, Ohio
    Locations
    122 in total
    Run by
    Exelixis

    See if you can join NCT05176483 on ClinicalTrials.gov

  4. Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

    The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subpro…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University Hospitals Cleveland Medical Center, Cleveland, Ohio
    Locations
    93 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT06162221 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.